A cluster of financing announcements and M&A activity this week underscores continued investor confidence in differentiated biologics platforms, with antibody-drug conjugates (ADCs), spatial omics and novel monoclonal antibodies each attracting significant capital.
Ona Therapeutics closes $86.6m Series B for first-in-class ADCs
Barcelona-based Ona Therapeutics has closed an oversubscribed $86.6m Series B to advance two first-in-class ADC programmes into and through clinical development.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.